Multiple Myeloma

Expert perspective on results from the MASTER trial, which analyzed dara-KRd as frontline therapy with MRD-adapted use in newly diagnosed multiple myeloma.

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines multiple myeloma research he hopes to see in the next 5 years.

For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses his research using real-world data from patients with triple-class refractory multiple myeloma.

Neutrophil to lymphocyte ratio may indicate the presence of frailty among older adults with multiple myeloma.

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines the importance of studying treatment resistant patients with multiple myeloma.

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.

Five years ago, investigators in Iceland sought to evaluate what would happen if screening for MGUS were widely available—and whether it would improve overall survival.

Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.

Real-world evidence from Japan found ixazomib has an acceptable safety profile in patients with relapsed/refractory multiple myeloma (RRMS).

Results of a retrospective study conducted in China assessed the safety and efficacy of ixazomib for multiple myeloma.

The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.

Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.

Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition.

Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.